http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/list Mynewsdesk nyhetsfeed direkt från källan http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Fri, 25 Jul 2008 13:15:00 +0200 Engagemang för andra utgör kärnan i Biogen Idecs grundläggande värderingar; djärvt nyskapande, kvalitet, integritet och ärlighet samt engagemang för dem vi arbetar för. ”Vi engagerar oss i patienter och deras vårdgivare, våra aktieägare och kollegor, och vi stödjer det samhälle vi lever och arbetar i på många sätt". http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-samhaellsengagemang-2047?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-samhaellsengagemang-2047?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB Fri, 25 Jul 2008 13:15:00 +0200 BiogenIdec har en produktportfölj med imponerande bredd och kvalitet inom terapiområden med stora medicinska behov. Företaget hade vid 2008 års början femton produkter i fas II eller senare. Biogen Idec bygger en internationell storskalig produktionsanläggning i Hillerød, Danmark, som beräknas stå klar under 2009. http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-forskningsportfoelj-2045?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-forskningsportfoelj-2045?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB Fri, 25 Jul 2008 13:15:00 +0200 Biogen Idec är världens tredje största bioteknikföretag. Företaget är internationellt ledande inom preklinisk forskning, utveckling, tillverkning och kommersialisering av innovativa terapimetoder. Företagets fokusområden är neurologi, onkologi och immunologi. På senare år har Biogen Idec även utvecklat forskningen inom nya terapiområden, bland annat hjärt- och kärlsjukdomar och hemofili. http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-fakta-om-foeretaget-2044?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-fakta-om-foeretaget-2044?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB Thu, 26 Jun 2008 08:53:00 +0200 The pathophysiology of MS drives the course of disease over time. Axonal loss correlate with neurologic disability and cognitive dysfunction, which in turn, correlate with brain atrophy. An increased relapse rate has been associated with disease progression and axonal loss may contribute to this. It is the loss of axons through demyelination that correlates with irreversible disability in MS. http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/the-pathophysiology-of-ms-1846?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/the-pathophysiology-of-ms-1846?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB Mon, 19 May 2008 08:42:00 +0200 Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, this week is celebrating its 30-year anniversary of creating new standards of care in therapeutic areas with high unmet medical needs. http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-celebrates-30-years-of-transforming-discovery-into-care-1907?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-celebrates-30-years-of-transforming-discovery-into-care-1907?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB Tue, 15 Apr 2008 08:24:00 +0200 Biogen Idec today announced that 17 company-sponsored plenary sessions, platform presentations, and poster presentations will be presented during the 60th Annual Meeting of the American Academy of Neurology. These presentations will cover four compounds that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS). http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-announces-multiple-sclerosis-franchise-and-pipeline-1906?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-announces-multiple-sclerosis-franchise-and-pipeline-1906?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB Thu, 14 Feb 2008 09:32:00 +0100 Biogen Idec and Cardiokine, Inc. today announced the initiation of a Phase III multi-center, randomized, placebo controlled, double-blind study of lixivaptan for congestive heart failure patients who suffer from hyponatremia. The trial will compare treatment with lixivaptan to placebo in approximately 650 patients in the U.S. and Europe. http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-and-cardiokine-initiate-phase-iii-clinical-trial-for-lixivaptan-in-congestive-1908?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/se/pressroom/biogenidec_sverige_ab/document/view/biogen-idec-and-cardiokine-initiate-phase-iii-clinical-trial-for-lixivaptan-in-congestive-1908?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Biogen Idec Sweden AB